NASDAQ:XLRN - Acceleron Pharma Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$50.00 -1.36 (-2.65 %)
(As of 11/14/2018 04:00 PM ET)
Previous Close$51.36
Today's Range$49.24 - $51.80
52-Week Range$32.53 - $59.59
Volume316,400 shs
Average Volume371,208 shs
Market Capitalization$2.39 billion
P/E Ratio-18.66
Dividend YieldN/A
Beta1.49
Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which is in Phase III clinical trials for the treatment of myelodysplastic syndromes and beta-thalassemia; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia and myelofibrosis. The company is also developing and sotatercept for the treatment of patients with pulmonary arterial hypertension. In addition, the company is developing ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with facioscapulohumeral dystrophy and Charcot-Marie-Tooth disease; and ACE-2494, which is in Phase I clinical trials for the treatment of systemic muscle disorders. It has a collaboration, license, and option agreement with Celgene Corporation. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.

Receive XLRN News and Ratings via Email

Sign-up to receive the latest news and ratings for XLRN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:XLRN
Previous Symbol
CUSIPN/A
Phone617-649-9200

Debt

Debt-to-Equity RatioN/A
Current Ratio21.68
Quick Ratio21.68

Price-To-Earnings

Trailing P/E Ratio-18.66
Forward P/E Ratio-19.92
P/E GrowthN/A

Sales & Book Value

Annual Sales$13.48 million
Price / Sales171.33
Cash FlowN/A
Price / CashN/A
Book Value$6.91 per share
Price / Book7.24

Profitability

EPS (Most Recent Fiscal Year)($2.68)
Net Income$-108,450,000.00
Net Margins-807.36%
Return on Equity-32.69%
Return on Assets-30.94%

Miscellaneous

Employees139
Outstanding Shares46,190,000
Market Cap$2.39 billion
OptionableOptionable

Acceleron Pharma (NASDAQ:XLRN) Frequently Asked Questions

What is Acceleron Pharma's stock symbol?

Acceleron Pharma trades on the NASDAQ under the ticker symbol "XLRN."

How were Acceleron Pharma's earnings last quarter?

Acceleron Pharma Inc (NASDAQ:XLRN) announced its earnings results on Tuesday, October, 30th. The biopharmaceutical company reported ($0.63) EPS for the quarter, beating analysts' consensus estimates of ($0.66) by $0.03. The biopharmaceutical company earned $3.30 million during the quarter, compared to analysts' expectations of $4.37 million. Acceleron Pharma had a negative return on equity of 32.69% and a negative net margin of 807.36%. The business's revenue was up 10.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.65) earnings per share. View Acceleron Pharma's Earnings History.

When is Acceleron Pharma's next earnings date?

Acceleron Pharma is scheduled to release their next quarterly earnings announcement on Tuesday, February 26th 2019. View Earnings Estimates for Acceleron Pharma.

What price target have analysts set for XLRN?

13 brokers have issued 1-year target prices for Acceleron Pharma's shares. Their predictions range from $33.00 to $75.00. On average, they expect Acceleron Pharma's stock price to reach $56.30 in the next twelve months. This suggests a possible upside of 12.6% from the stock's current price. View Analyst Price Targets for Acceleron Pharma.

What is the consensus analysts' recommendation for Acceleron Pharma?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acceleron Pharma in the last year. There are currently 5 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Acceleron Pharma.

What are Wall Street analysts saying about Acceleron Pharma stock?

Here are some recent quotes from research analysts about Acceleron Pharma stock:
  • 1. Cann analysts commented, "Loss per share was $0.63 compared to our estimated loss of $0.57. The slightly higher than estimated loss was the result of R&D expenses of $24.7 million being 14.6% higher than our estimated $21.5 million. This was partially offset by higher estimated collaboration revenue and higher interest income. There were no other remarkable variances in the quarter. Our outlook for revenue remains basically unchanged. We are making modest adjustments to operating expenses, by increasing estimated R&D expense by nearly 10% per year in 2018-2022." (10/31/2018)
  • 2. HC Wainwright analysts commented, "We are lowering our price target to $73, from $74, due to our lower YE18 cash estimate. The price target is based on probability-adjusted revenue forecasts for luspatercept, the company’s earlier stage pipeline and estimated year-end cash. We use the net present value of our revenue forecast through 2026, apply a 65% probability of success and a 2.5x price/sales multiple for luspatercept, and our year-end cash estimate to arrive at our price target." (8/3/2018)

Has Acceleron Pharma been receiving favorable news coverage?

Media coverage about XLRN stock has trended somewhat positive recently, InfoTrie reports. The research group scores the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Acceleron Pharma earned a daily sentiment score of 1.4 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the company's share price in the next few days.

Who are some of Acceleron Pharma's key competitors?

Who are Acceleron Pharma's key executives?

Acceleron Pharma's management team includes the folowing people:
  • Mr. Habib J. Dable, CEO, Pres & Director (Age 49)
  • Dr. Thomas P. Maniatis, Co-Founder, Member of Scientific Advisory Board & Director (Age 75)
  • Mr. Kevin F. McLaughlin, CFO, Sr. VP & Treasurer (Age 62)
  • Dr. Ravindra Kumar, Chief Scientific Officer & Sr. VP (Age 58)
  • Dr. John D. Quisel, Exec. VP, Chief Bus. Officer & Sec. (Age 47)

Who are Acceleron Pharma's major shareholders?

Acceleron Pharma's stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (14.94%), BlackRock Inc. (9.41%), Janus Henderson Group PLC (3.02%), Artal Group S.A. (2.16%), Eagle Asset Management Inc. (1.91%) and Brown Advisory Inc. (1.15%). Company insiders that own Acceleron Pharma stock include Christopher Rovaldi, Corp /De/ Celgene, Jean George, John D Quisel, Joseph S Zakrzewski, Kevin F Mclaughlin, Matthew L Sherman, Ravindra Kumar, Richard F Pops, Steven D Ertel and Terrance Mcguire. View Institutional Ownership Trends for Acceleron Pharma.

Which major investors are selling Acceleron Pharma stock?

XLRN stock was sold by a variety of institutional investors in the last quarter, including Artal Group S.A., AXA, Baker BROS. Advisors LP, Pictet Asset Management Ltd., Prudential Financial Inc., Foresite Capital Management III LLC, Foresite Capital Management II LLC and DekaBank Deutsche Girozentrale. Company insiders that have sold Acceleron Pharma company stock in the last year include Christopher Rovaldi, Jean George, John D Quisel, Kevin F Mclaughlin, Matthew L Sherman and Richard F Pops. View Insider Buying and Selling for Acceleron Pharma.

Which major investors are buying Acceleron Pharma stock?

XLRN stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Janus Henderson Group PLC, BlackRock Inc., Stanley Laman Group Ltd., EAM Investors LLC, First Trust Advisors LP, Candriam Luxembourg S.C.A. and Comerica Bank. Company insiders that have bought Acceleron Pharma stock in the last two years include Corp /De/ Celgene and Joseph S Zakrzewski. View Insider Buying and Selling for Acceleron Pharma.

How do I buy shares of Acceleron Pharma?

Shares of XLRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Acceleron Pharma's stock price today?

One share of XLRN stock can currently be purchased for approximately $50.00.

How big of a company is Acceleron Pharma?

Acceleron Pharma has a market capitalization of $2.39 billion and generates $13.48 million in revenue each year. The biopharmaceutical company earns $-108,450,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis. Acceleron Pharma employs 139 workers across the globe.

What is Acceleron Pharma's official website?

The official website for Acceleron Pharma is http://www.acceleronpharma.com.

How can I contact Acceleron Pharma?

Acceleron Pharma's mailing address is 128 SYDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-9200 or via email at [email protected]


MarketBeat Community Rating for Acceleron Pharma (NASDAQ XLRN)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  391 (Vote Outperform)
Underperform Votes:  251 (Vote Underperform)
Total Votes:  642
MarketBeat's community ratings are surveys of what our community members think about Acceleron Pharma and other stocks. Vote "Outperform" if you believe XLRN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XLRN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/14/2018 by MarketBeat.com Staff

Featured Article: Discount Rate

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel